Radioembolization to Treat Primary and Metastatic Liver Tumors
Trial Snapshot
- Phase
- Not Applicable
- Status
- Withdrawn
- Sponsor
- Methodist Health System
- Enrollment
- 100
- Locations
- 1
- Primary Endpoint
- time to recurrence
Study Overview
Brief Summary
The use of Radiospheres in the management of intrahepatic cholangiocarcinoma is largely unknown and not reported in the medical literature. Methodist Dallas Medical Center has a large volume of IR procedures with Radioembolization and the investigators feel it is imperative to understand the outcomes, risks and benefits of the therapy in order to formulate recommendation to other centers.
Detailed Description
A retrospective chart review of patients who have the diagnosis of intrahepatic cholangiocarcinoma. Only patients treated at MDMC are included and data will be obtained from Meditech and Epic. A non-identified database of cases with the diagnosis of intrahepatic cholangiocarcinoma already treated with radiospheres will be created and compared with cases treated by other means.
Intrahepatic cholangiocarcinoma is the second most common primary malignancy of the liver. The standard therapy has been resection but many cases are not resectable due to comorbidities or other poor surgical candidacy factors. Most of these patients end up getting chemotherapy which can be toxic and sometimes poorly tolerated. Intrarterial glass or resin radioembolization has been used and published from only 3 centers in the medical literature and it has been shown to be a reasonable alternative to the above options. At MDMC, this therapy has been used effectively and it is important to describe the investigator's experience.
Study Design
- Study Type
- Observational
- Observational Model
- Cohort
- Time Perspective
- Retrospective
Eligibility Criteria
- Ages
- 18 Years to — (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •Patients with the diagnosis of intrahepatic cholangiocarcinoma from January 2006 until April 2017 at Methodist Dallas Medical Center (MDMC)
- •Patients 18 years old or older
Exclusion Criteria
- •Patients without the diagnosis of intrahepatic cholangiocarcinoma
- •Patients under 18 years of age
Outcomes
Primary Outcomes
time to recurrence
Time Frame: January 2006 until April 2017
time to recurrence
review the outcomes of patients treated with radiospheres
Time Frame: January 2006 until April 2017
Patient survival
Secondary Outcomes
No secondary outcomes reported